Kornimate/medical-research-clean huggingface dataset:
vaginal isonicotinic acid hydrazide prior to diagnostic office hysteroscopy in primarily infertile patients

Conditions: Infertility, Female

Summary: to compare the effectiveness of vaginal isonicotinic acid hydrazide with placebo in minimizing the pain experienced by primarily infertile patients during diagnostic ofﬁce hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopist.

hysteroscopy is commonly used in the diagnosis and treatment of intrauterine lesions such as polyps, ﬁbroids, septa, and adhesions, and in the presence of abnormal bleeding and during the removal of an intrauterine device or foreign body. cervical ripening is made possible by the use of medication through different routes.

Eligibility criteria:
inclusion criteria: * nulliparous women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup exclusion criteria: * women with suspected pregnancy * heavy vaginal bleeding * recent pelvic infection * those known to have hypersensitivity or contraindication to isonicotinic acid hydrazide * those who received analgesics prior to office heavy vaginal bleeding * recent pelvic infection * a concomitant neurologic disease that could affect the correct evaluation of pain
effectiveness of airrosti and theraband exercises on double-crossed syndrome in smart phone user's shoulder

Conditions: Rounded Shoulder Posture

Summary: double-crossed syndrome" refers to a specific alignment of overactive and underactive muscles in the neck, chest, and shoulders. airrosti stands for applied integration for the rapid recovery of soft tissue injuries. this study aims to evaluate the effectiveness of airrosti exercises combined with theraband exercises in reducing pain and disability in the neck and shoulders. theraband exercise programs are commonly used to improve muscle activation. however, research on the effectiveness of airrosti combined with theraband exercises for treating double-crossed syndrome among smartphone users is limited, and more evidence is needed to support their effectiveness.

research objective is to evaluate the effectiveness of airrosti and theraband exercises in reducing pain and disability among smartphone users with double-crossed syndrome. to evaluate the combined effect of airrosti and theraband exercises in reducing pain and disability among smartphone users with double-crossed syndrome. to compare the effect of airrosti and theraband exercises in reducing pain and disability among smartphone users with double-crossed syndrome.

Eligibility criteria:
inclusion criteria: young female participants with rounded shoulder postures. participants aged between 18 and 25 years. no history of shoulder trauma, current shoulder pathology, thoracic scoliosis, and kyphosis deformity. exclusion criteria: participants excluded if they received any other form of medical treatment or have thoracic scoliosis or kyphosis deformity.

Keywords: double crossed syndrom posture smart phone users
prevention of breast cancer: as simple as hcg-a randomized clinical trial in high risk women

Conditions: Breast Cancer

Summary: the purpose of the study is to evaluate whether hcg will result in a decrease in breast density. high breast density has been associated with an increased risk in breast cancer. it has also been shown that decreasing density with a drug called tamoxifen has resulted in a decreased risk in breast cancer. the investigators are looking at the effect of hcg on breast density in people who are at increased risk of developing breast cancer and our theory postulates that through the hormonal actions of hcg and tamoxifen there would be a greater reduction in breast density in patients who are treated with hcg and tamoxifen versus patients treated with tamoxifen alone. using this data the investigators will be able to hypothesize that the treatment of hcg will result in a reduction in breast cancer rates in the population and thus make available another drug which can be used to decrease the rates of breast cancer in the population

pregnancy has been associated with a decreased risk of breast cancer. this has been reproduced in multiple studies and has been seen in multiple races. people have been evaluating different hormones and practices associated with pregnancy to determine what factors reduce the risk of developing breast cancer in these patients. these pronounced findings have been evaluated in great detail by multiple scientists and one of the hormones which we think might be associated with a reduction in breast cancer is hcg. this statement has been backed by multiple studies which have looked at the direct effect of hcg on the growth and death of breast cancer cells in the lab and in animal models of breast cancer. we want to determine if hcg is given to patients who are at increased risk of breast cancer will result in an accentuated decrease in breast cancer risk above and beyond the effect received by conventional breast cancer reducing protocols. our final outcome in this study will be breast density on mammographic evaluation which is considered a marker for breast cancer. so our study will evaluate whether or not hcg will have an effect on the mammographic breast density. after recruitment there will be two groups in our study an intervention group and non intervention group. in the intervention group patients would undergo a period of hcg injections which would last a total of 60 days and consist of 30 subcutaneous injections. the non intervention group will continue their conventional chemoprevention medication. both groups will be followed for teo years and the images, cytology and blood samples will be sent to our labs for evaluation.

Eligibility criteria:
inclusion criteria: * on tamoxifen therapy for the treatment or prevention of breast cancer. * must have at least one remaining breast. exclusion criteria: * pregnant or nursing. * no history of allergic reactions to hcg. * patients who have had bilateral mastectomies. * uncontrolled thyroid disease. * cognitively impaired and unable to consent for the trial.

Keywords: breast cancer chemoprevention tamoxifen breast density hcg
effect of aerobic exercise training on balance, walking capacity, and quality of life in sub-acute stroke.

Conditions: Cerebrovascular Stroke; Cerebrovascular Accident, Acute; Cerebral Stroke

Summary: stroke is one of the major cause of morbidity and mortality and the leading cause of disability in adults all around the world. stroke survivors can suffer several neurological impairments and deficits which have an important impact on patient's quality of life and which increase the costs for health and social services. after stroke, impairments in adls and functional status, deterioration in health related quality of life can be seen. the purpose of this study is to determine the effect of aerobic exercise training on balance, walking capacity and quality of life in sub-acute stroke.


Eligibility criteria:
inclusion criteria: * 18 to 75 years of age. * stroke that occurred in the recent 3 months. * who can walk independently or by using assistive device. * have a minimum chedoke mcmaster stroke assessment (cmsa) leg impairment score of 3 but less than 7. exclusion criteria: * patients were excluded from the study if they have a stroke that occurs more than 3 months. * if resting blood pressure more than 160/100 even after taking medications * have by-pass surgery in recent 3 months. * other musculoskeletal problems which restrict the patient's ability to do aerobic activity.

Keywords: aerobic exercise stroke walking capacity
anti-proliferative effects of vitamin d and melatonin in breast cancer

Conditions: Early Stage Breast Cancer

Summary: investigators plan to carry out a study to investigate two different pills, vitamin d and melatonin, and whether they can reduce the spread of cancer cells in the tumors of women with breast cancer. these pills are inexpensive and have very few side effects. a large number of studies using cell cultures and animals have shown that both vitamin d and melatonin can help destroy breast cancer cells. however thoughtful and well-designed studies are necessary on humans to see if they can decrease the spread of breast cancer, and possibly even prevent breast cancer. the proposed study aims to understand the anti-cancer activity of vitamin d and melatonin. this knowledge will assist in creating efficient cancer prevention strategies for canadians. this study will include women with breast cancer who are being planned for surgery, and will assess whether treatment with vitamin d (dose of 2000 iu per day) in a group of 36 women, or melatonin (dose of 20mg per day) in another group of 36 women, or both pills together in yet another group of 36 women, reduces the spread of cancer cells when compared to a fourth group of 36 women who are treated with sugar pills. to do this we will measure a substance in the blood called ki67, which provides information about the spread of cancer. investigators will compare the ki67 levels in the 4 groups, and all women will receive identical appearing pills so they will not know which treatment they received.


Eligibility criteria:
inclusion criteria: * woman with histologically confirmed invasive breast cancer (ductal, lobular, or mixed) * planned to undergo definitive surgery, either lumpectomy or mastectomy in 3 or more weeks exclusion criteria: * less than 18 years of age * stage iiib or iv disease * inoperable locally advanced or metastatic breast cancer * neoadjuvant chemotherapy is intended * currently taking vitamin d supplements * currently taking melatonin supplements * previously taking vitamin d or melatonin supplements within the last 3 months * currently taking a multivitamin and not willing to discontinue for the duration of the study * hyperparathyroid disease or other calcium disturbance in the past five years * active renal stones in the last six months * renal failure (creatinine \> 190 mmol/l) * hypercalcemia (serum calcium \> 2.6 mmol/l) * known pregnancy * participation in another clinical trial where the patient receives any other investigational product * unwilling or unable to provide informed consent

Keywords: breast cancer melatonin vitamin d ki67
impact of smoking on salivary interleukin (il)-39, il-41, il-1β, tnf-α levels in periodontal disease

Conditions: Periodontitis, Adult; Smoking; Periodontal Diseases

Summary: the goal of this observational study is to evaluate if the measurement of salivary interleukin (il)-39, il-41, il-1beta(β), and tumor necrosis factor-alpha (tnf-α) levels can aid in the early diagnosis of periodontitis in patients with varying periodontal conditions, both smokers and non-smokers. the main questions it aims to answer are: can salivary il-39, il-41, il-1β, and tnf-α levels be used as biomarkers for the early diagnosis of periodontitis? how do il-41 and il-39 levels correlate with smoking status in periodontal healthy and periodontitis patients? researchers will compare the salivary biomarker levels between smokers and non-smokers to see if smoking affects these levels. participants will: provide salivary samples for biomarker analysis. undergo a comprehensive periodontal examination to determine their periodontal status.


Eligibility criteria:
inclusion criteria: * the periodontitis groups (non-smoking and smoking) in the study will include systemically healthy patients who are clinically diagnosed with stage ii and iii, generalized, grade b, c periodontitis based on the consensus report of the 2017 world workshop on classification of periodontal and peri-implant diseases and conditions. * agreeing to participate in the study exclusion criteria: * use of oral contraceptive drugs * use of antibiotics, immunosuppressants, or drug therapies in the last 6 months before the study; * history of excessive alcohol use; * pregnancy or breastfeeding status; * periodontal treatment during the last 6 months before the study. * not agreeing to participate in the study * not meeting the inclusion criteria

Keywords: periodontitis cytokines saliva
epidemiological emesis-registry

Conditions: Antiemetic Therapy

Summary: the purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in germany. the outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.


Eligibility criteria:
inclusion criteria: * moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid. * start with the 1st cycle of the regimen (chemo naive patients). inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given \>= 24 months ago. * compliance with registry procedures * age \>= 18 years * who performance status of 0 or 1 (karnofsky-index \>= 70%) * life expectancy of at least 12 weeks * signed and dated informed consent before the start of the registry exclusion criteria: * mentally incapable or incompliant patients * last chemotherapy \<= 24 months (if pretreated) * known hypersensitivity to antiemetic medication * unability of the patient to be treated with oral medication * pregnancy or lactation period

Keywords: antiemetic therapy emesis vomiting nausea moderately and highly emetogenic chemotherapy cisplatin carboplatin oxaliplatin anthracycline cyclophosphamid
a study of ranolazine in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of als.

a prospective, multi center, double-blind, placebo-controlled, parallel group study of 2 doses of ranolazine (500 mg and 1000 mg twice daily) compared to placebo in patients with als. approximately 72 adults with als will be enrolled into the study in the united states at approximately 7 als treatment sites. participants will take oral ranolazine or placebo twice daily, attend a minimum of 5 onsite research visits, and 4 remote research visits. the study is estimated to last 28 weeks for each participant.

Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosed with clinically definite, possible, probably, or lab-supported probable als per revised el escorial criteria * breathing assessment called forced vital capacity (fvc) greater than or equal to 50%. * able to swallow pills at the start of the study and expected to for the length of the study. * if on als modifying medications must be on a stable dose at least 30 days. * experiencing 4 or more cramps per week during a 2-week screening period. exclusion criteria: * disease duration \< 5 years * tracheostomy invasive ventilation, or noninvasive ventilation of more than 12 hours/day * pregnant or lactating, adults unable to consent, and prisoners * taking ranolazine or investigational drug or has received an investigational drug within 30 days (or 5 half-lives for drugs, whichever is longer) prior to screening * medically uncontrolled comorbidities (heart, liver, kidney disease) * baseline qtc interval prolongation \>450 ms for men/ \>470 ms for women, history of long qt syndrome, or medications which prolong the qt interval * participation in an experimental drug trial less than 30 days before screening * patients have to be on a stable dosage of any medications used to treat muscle cramps for ≥30 days or have been off these medications ≥30 days prior to randomization.

Keywords: als motor neuron disease lou gehrig's disease placebo-controlled
18f-fspg pet/ct imaging in patients with cancers

Conditions: Pulmonary Cancer; Breast Neoplasms; Abdominal Cancer

Summary: this study aims to compare the diagnostic performance of 18f-fdg and 18f-fspg pet/ct in lung, breast, and abdominal cancers before undergoing therapy. in addition, the role of 18f-fspg pet/ct in evaluating therapy response and prognosis will also be evaluated.


Eligibility criteria:
inclusion criteria: * patients are given the opportunity to participate in the study if 1. age ≥ 20 years old. 2. confirmed diagnosis of primary cancer of the following: nsclc, breast or abdominal cancers 3. ecog performance status 0 to 2. 4. life expectancy \> 3 months. 5. consent to perform additional 18f-fspg and 18f-fdg pet prior to therapy. 6. sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks. exclusion criteria: * patients with any of the following conditions will be excluded 1. had received previous treatment (excluding neoadjuvant therapy). 2. pregnant or lactating women. 3. known malignancy in other organs. 4. evaluated by primary care physician as unsuitable. 5. known hypersensitivity to the study drug.

Keywords: (4s)-4-(3-[18f]fluoropropyl-)-l-glutamate 18f-fspg pet/ct system xc-transporter
vitamin d for critically traumatic patients

Conditions: Vitamin D Deficiency; Major Trauma

Summary: trauma has been an important global public health issue. yet it is the sixth cause of death in taiwan, trauma brings great negative impact to national productivity since it presents specifically as the leading cause of death for the population aged below 40 years. according to the national databank from formosa association for the surgery of trauma, mortality rate in critically traumatic patients with injury severity score (iss) ≥ 25 is as high as 23%. vitamin d, a pleiotropic hormone, regulates directly functions of most organs and immune system. it has been proven that vitamin d insufficiency or deficiency would deteriorate survival of critically ill patients, while supplementation of high-dose vitamin d ameliorates the clinical outcomes. this study investigates whether multiple high doses of vitamin d supplementation in one week can decrease the mortality and morbidity in critically traumatic patients. the serum levels of calcidiol and pth will be measured on day 0, day 3, day 10, day 15, day 30 and day 60 before and after vitamin d supplementation.


Eligibility criteria:
inclusion criteria: * major trauma adult (\> 20 years old) with injury severity score equal or higher than 9, who is admitted to icu exclusion criteria: patients with the following conditions: * chronic liver disease * contraindication to enteral feeds * hypercalcemia * current use of vitamin d, estrogen, or medications for bone disease * high risk of hypercalcemia, ex. metastatic cancer, primary hyperparathyroidism, sarcoidosis, multiple myeloma

Keywords: vitamin d major trauma
preventing diabetes in latino families

Conditions: Type 2 Diabetes; Obesity; Pediatric Obesity

Summary: purpose: this study will test the efficacy of a family-focused lifestyle intervention for reducing type 2 diabetes (t2d) risk factors and increasing quality of life (qol) among high-risk latino families.

background: t2d disproportionately impacts latino children, families and communities. the diabetes prevention program (dpp) established that t2d can be prevented in high-risk adults through intensive lifestyle intervention. although the dpp has been translated to a variety of adult populations and settings, engagement and effectiveness is diminished in minority communities and there are no family-focused diabetes prevention trials for latinos. the culturally-grounded approach is guided by an ecodevelopmental model that considers community, family, peer, and individual-level factors that influence health behaviors and health outcomes over time. the study will test the efficacy of a 16-week family-focused lifestyle intervention for reducing t2d risk and increasing qol among high-risk latino families as compared to control families. the study will use integrative mixed methods to understand how family structures and processes influence intervention outcomes.

Eligibility criteria:
inclusion/exclusion criteria - children inclusion * latino: self-report * age: 10-16 years * obesity: bmi ≥ 95th percentile for age and sex exclusion * type 2 diabetes: (standard american diabetes association criteria) * taking medication(s) or diagnosed with a condition that influences carbohydrate metabolism, physical activity, and/or cognition * currently enrolled in (or within previous 12 months) a formal diabetes prevention or weight loss program * self-identify as american indian * unstable depression or other mental health condition that may impact qol ii. inclusion/exclusion criteria - parents inclusion • parent of a child who meets the above child inclusion/exclusion criteria exclusion * currently enrolled in (or within previous 12 months) a formal diabetes prevention or weight loss program * self-identify as american indian
swissnet - a registry for neuroendocrine tumours in switzerland

Conditions: Neuroendocrine Tumors; Carcinoid Tumor

Summary: gastroentero-pancreatic neuroendocrine tumours (gep-nets) are regarded as a fairly rare disease. they are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. so far, there is still uncertainty about the cell biology and mechanistic regulation of these tumours. therefore targeted treatment is limited and management challenging. treatment options include surgery, medical and ablative therapy, and more recently peptide-receptor radionuclide therapy. in order to better understand the characteristics of gep-nets and to evaluate treatment strategies, the swissnet registry aims at the collection of data from patients presenting with a gep-net in switzerland. data will be entered prospectively and anonymized in a specifically designed database after the patient has given informed consent. all hospitals and general practitioners are invited to report on patients with a gep-net diagnosis and to participate to the registry. data will be evaluated within regular time frames, focussing on types of gep-nets, treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate), thereby contributing to the better understanding of these tumours.

background gastroentero-pancreatic neuroendocrine tumours (gep-nets) are generally classified as rare diseases. little is known about their cell biology and their mechanistic regulation. during the last years, the incidence of gep-nets is continuously increasing worldwide. in parallel, novel treatment options are currently evaluated which may substantially improve prognosis of patients with nets. data on such tumours in switzerland, however, is scarce and treatment strategies vary throughout the country. objective to systematically and prospectively collect clinical information of patients with gep-nets in switzerland based on a histologically confirmed diagnosis. methods all nets of both, gastrointestinal and pulmonary origin are included provided that patients have given informed consent. data will be entered prospectively and anonymised in a specifically designed database. contributing centres and general practitioners are visited by a study nurse, patient files are analysed and data is transferred to the database. in case of conflicting evidence, questions are resolved in collaboration with a review board of swissnet. evaluation of treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate) will take place within regular time frames.

Eligibility criteria:
inclusion criteria: * neuroendocrine tumor irrespective of primary tumor location * diagnosis in switzerland * given informed consent

Keywords: neuroendocrine tumors registries